Bad Reaction to Remark on Drug Firms
I was aghast at the comment by analyst Robert Wasserman, and represented by Barbara Marsh in her article Oct. 6, that four pharmaceuticals acquired by ICN Pharmaceuticals from Roche Holdings are “a bunch of crap.”
I seriously doubt whether the patients worldwide who rely on these pharmaceuticals for the treatment of cancer, epilepsy, gastrointestinal ailments and serious sleep disorders would agree with that assessment.
The opinion of one of the physicians who regularly prescribe these valuable pharmaceuticals surely would have been more valid than that of someone whose field of expertise is financial analysis. The comment was disingenuous and uninformed.
Dr. FUSUN ZEYTIN
Vice president,
corporate development
ICN Pharmaceuticals Inc.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
